Cardiopoietic Stem Cell Therapy in Heart Failure: The C-CURE (Cardiopoietic stem Cell therapy in heart failURE) Multicenter Randomized Trial With Lineage-Specified Biologics.

Bartunek, Jozef;Behfar, Atta;Dolatabadi, Dariouch;Vanderheyden, Marc;Terzic, Andre;et.al.
(2013) Journal of the american college of cardiology : JACC — Vol. 61, n° 23, p. 2329-2338 (2013)

Files

JAmCollCardiol20136123292338.pdf
  • Restricted Access
  • Adobe PDF
  • 1.3 MB
Request a copy

Details

Authors
  • Bartunek, Jozef
    Author
  • Behfar, Atta
    Author
  • Dolatabadi, Dariouch
    Author
  • Vanderheyden, Marc
    Author
  • Vanoverschelde, Jean-LouisUCLouvain
    Author
  • Terzic, Andre
    Author
Show more
Abstract
The C-CURE trial implements the paradigm of lineage guidance in cell therapy. Cardiopoietic stem cell therapy was found feasible and safe with signs of benefit in chronic heart failure, meriting definitive clinical evaluation. (C-Cure Clinical Trial; NCT00810238).
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Bartunek, J., Behfar, A., Dolatabadi, D., Vanderheyden, M., Ostojic, M., Dens, J., El Nakadi, B., Banovic, M., Beleslin, B., Vrolix, M., Legrand, V., Vrints, C., Vanoverschelde, J.-L., Crespo-Diaz, R., Homsy, C., Tendera, M., Waldman, S., Wijns, W., & Terzic, A. (2013). Cardiopoietic Stem Cell Therapy in Heart Failure: The C-CURE (Cardiopoietic stem Cell therapy in heart failURE) Multicenter Randomized Trial With Lineage-Specified Biologics. Journal of the american college of cardiology : JACC, 61(23), 2329-2338. https://doi.org/10.1016/j.jacc.2013.02.071 (Original work published 2013)